Osaka, Japan – Parkinson’s disease is a neurodegenerative disease caused by the loss of neurons that produce dopamine, a neurotransmitter involved in motor control and cognitive function. As the global population ages, the number of Parkinson’s disease patients is rapidly increasing. Parkinson’s disease is induced by neuronal damage due to...
Latest News
WASHINGTON, DC — Adults with type 2 diabetes on a low-carbohydrate diet may see benefits to their beta-cell function allowing them to better manage their disease and possibly discontinue medication, according to new research published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Beta-cells are endocrine cells in the...
Chicago, Illinois – A new antibiotic that works by disrupting two different cellular targets would make it 100 million times more difficult for bacteria to evolve resistance, according to new research from the University of Illinois Chicago. For a new paper in Nature Chemical Biology, researchers probed how a class of synthetic...
Ann Arbor, Michigan – A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance. The design and preclinical evaluation of the inhibitor, MTX-531 was published in Nature Cancer. Researchers, led by...
Nottingham, UK – New research into a chemical produced by a caterpillar fungus that has shown promise as a possible cancer treatment has revealed how it interacts with genes to interrupt cell growth signals. The discovery is an important step towards developing new drugs for the treatment of the disease....
IRVING, Texas -Acentrus Specialty™, a national network of health systems and hospitals committed to providing specialty pharmacy care for their patients, has finalized an agreement with Chiasma, Inc. (NASDAQ: CHMA) to provide qualified Acentrus clients access to MYCAPSSA® (octreotide), delayed-release oral capsules for long-term maintenance treatment in acromegaly patients who...
ALAMEDA, Calif. and TAIPEI — Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms to address gaps in cancer care, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s...
New York, NY – Achalasia is primarily caused by the degeneration of the myenteric plexus in the esophageal wall, leading to impaired relaxation of the lower esophageal sphincter (LES) and loss of esophageal peristalsis. Although the exact etiology is not fully understood, it is believed to involve autoimmune mechanisms and...
LONDON, UK — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON study in advanced unresectable or metastatic...
PALO ALTO, Calif. — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, presented data from the ATTRibute-CM study showing that acoramidis reduced cumulative cardiovascular outcomes, including cardiovascular mortality (CVM) or recurrent cardiovascular-related hospitalizations (CVH), within the first month of...